Sign Up
OverviewAPI
AltPep, a Seattle biotech startup, has developed a promising test, SOBA-AD, for early detection of Alzheimer’s, achieving 100% success in symptomatic patients. The company aims for FDA approval within 12 months, securing $76 million in funding and recognition for innovation.

Ask a question